hdhodh

hDHODH-IN-5 is an inhibitor of human dihydroorotate dehydrogenase (hDHODH, IC50 = 0.91 μM).

hDHODH-IN-1 is a human dihydroorotate dehydrogenase (hDHODH) inhibitor exhibiting anti-inflammatory properties.

hDHODH-IN-8 is a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 16 nM, exhibiting significant antiproliferative activity and excellent aqueous solubility, and holds potential for tumor disease research, particularly lymphoma.

hDHODH-IN-3 is an inhibitor of human dihydroorotate dehydrogenase with a pMIC50 value of 8.6. hDHODH-IN-3 can inhibit measles virus replication.

hDHODH-IN-4 (DHODH-IN-5) is a potent inhibitor of human dihydrogen dehydrogenase (DHODH). For human recombinant DHODH, its pIC50 is 7.8. hDHODH-IN-4 inhibits measles virus replication with a pMIC50 of 8.8.

hDHODH-IN-7 (DHODH-IN-9) is a nitrogen-containing analog and is a human dihydrorotatory dehydrogenase inhibitor. hDHODH-IN-7 and pMIC50 of 7.4 have antiviral effects.

hDHODH-IN-2, an analogue of the active metabolite of Leflunomide, is a human dihydroorotate dehydrogenase (hDHODH) inhibitor with anti-inflammatory activity.

hDHODH-IN-16 (Compound 3t) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH) with an IC50 of 0.11 μM. It demonstrates very low cytotoxicity towards healthy HaCaT cells, with an IC50 value exceeding 200 μM.

hDHODH-IN-17 (Compound 10) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH), with an IC50 value of 0.188 μM. It fits well with the hDHODH active site and interacts effectively with amino acid residues. hDHODH-IN-17 is a potential broad-spectrum antiviral drug.

hDHODH-IN-9 (Compound 3k) is a highly potent hDHODH inhibitor with an IC50 of 0.34 μM, demonstrating significant cytotoxic activity against MCF-7 and A375 cells while maintaining good selectivity, making it a promising candidate for cancer disease research [1].

hDHODH-IN-10 is a selective, orally active, potent hDHODH inhibitor (IC50: 10.9 nM) that forms hydrogen bonds with key residues Arg136 and Gln47. It inhibits cancer cell proliferation and can be used to study cancers (e.g. AML, colon cancer).

hDHODH-IN-11, a potent inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibits an IC50 value of 7.2 nM and has low cytotoxicity. It is applicable in acute myeloid leukemia (AML) research.

hDHODH-IN-12 is a potent inhibitor of dihydroorotate dehydrogenase (DHODH), exhibiting an inhibitory concentration (IC50) of 0.421 μM. As the rate-limiting enzyme in the de novo synthesis of pyrimidines, critical for DNA RNA synthesis, DHODH is localized within the inner membrane of human mitochondria. hDHODH-IN-12 is applicable in lung cancer research [1].

hDHODH-IN-13 (compound w2), an inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibits an IC50 of 173.4 nM and has potential research applications in studying inflammatory bowel disease (IBD) [1].

Compound 14 (hDHODH-IN-14) is an inhibitor of human dihydroorotate dehydrogenase (hDHODH), exhibiting an IC50 value of 0.469 μM [1].

hDHODH-IN-15 (Compound H19) acts as an inhibitor of human dihydroorotate dehydrogenase (hDHODH), demonstrating an IC50 of 0.21 µM. It exhibits cytotoxic effects in cancer cells such as NCI-H226, HCT-116, and MDA-MB-231, with IC50 values ranging from 0.95 to 2.81 µM. Furthermore, hDHODH-IN-15 induces ferroptosis in HCT-116 cells and shows antitumor activity.

Ascochlorin A, a compound with a dissociation constant (K D) of 3.29 μM, serves as a novel and potent human dihydroorotate dehydrogenase (hDHODH) inhibitor aimed at treating triple-negative breast cancer.